Accelerate Diagnostics, Inc. (AXDX) Given Consensus Recommendation of “Buy” by Brokerages

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has earned an average broker rating score of 1.50 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company.

Brokers have set a 12 month consensus price target of $26.50 for the company and are anticipating that the company will post ($0.31) EPS for the current quarter, according to Zacks. Zacks has also given Accelerate Diagnostics an industry rank of 183 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

Several brokerages have recently weighed in on AXDX. BidaskClub upgraded shares of Accelerate Diagnostics from a “hold” rating to a “buy” rating in a report on Thursday, February 22nd. Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Monday, January 15th. ValuEngine upgraded shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, BTIG Research lowered shares of Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 13th. They noted that the move was a valuation call.

In other Accelerate Diagnostics news, Director Jack W. Schuler bought 15,000 shares of the stock in a transaction that occurred on Thursday, March 1st. The shares were bought at an average price of $25.15 per share, for a total transaction of $377,250.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Jack W. Schuler bought 20,000 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was acquired at an average price of $24.95 per share, for a total transaction of $499,000.00. The disclosure for this purchase can be found here. Insiders purchased a total of 45,100 shares of company stock worth $1,130,850 in the last 90 days. 50.00% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of AXDX. Cpwm LLC acquired a new stake in shares of Accelerate Diagnostics in the 4th quarter worth about $202,000. UBS Asset Management Americas Inc. acquired a new stake in shares of Accelerate Diagnostics in the 4th quarter worth about $233,000. Teacher Retirement System of Texas acquired a new stake in shares of Accelerate Diagnostics in the 4th quarter worth about $292,000. MetLife Investment Advisors LLC acquired a new stake in shares of Accelerate Diagnostics in the 4th quarter worth about $297,000. Finally, SeaCrest Wealth Management LLC acquired a new stake in shares of Accelerate Diagnostics in the 4th quarter worth about $643,000. Institutional investors own 44.86% of the company’s stock.

AXDX traded up $0.05 during trading on Friday, reaching $23.25. 323,075 shares of the stock traded hands, compared to its average volume of 194,547. The stock has a market capitalization of $1,296.56, a P/E ratio of -20.04 and a beta of 2.13. Accelerate Diagnostics has a 12 month low of $16.75 and a 12 month high of $30.45.

Accelerate Diagnostics (NASDAQ:AXDX) last issued its quarterly earnings results on Thursday, February 15th. The medical research company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.05. Accelerate Diagnostics had a negative net margin of 1,520.99% and a negative return on equity of 54.66%. The business had revenue of $2.10 million for the quarter. research analysts forecast that Accelerate Diagnostics will post -1.2 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/accelerate-diagnostics-inc-axdx-given-consensus-recommendation-of-buy-by-brokerages.html.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Get a free copy of the Zacks research report on Accelerate Diagnostics (AXDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply